Moses A M, Moses L K, Notman D D, Springer J
J Clin Endocrinol Metab. 1981 May;52(5):910-3. doi: 10.1210/jcem-52-5-910.
Desmopressin (dDAVP) is a synthetic analog of arginine vasopressin which generally has been very effective, used intranasally, in the treatment of diabetes insipidus. There are several clinical situations, however, where a parenteral route of administration would be preferable. Using 6 patients with diabetes insipidus, we have shown a dose-response relationship between 0.5 and 4 microgram of dDAVP injected sc. The nonsteroidal, antiinflammatory agent, indomethacin, augments the magnitude, but not the duration, of the response to 0.5 microgram dDAVP. These observations suggest that injected dDAVP, generally in the amount of 1 or 2 microgram, would be a valuable agent in the treatment of diabetes insipidus and that combined therapy with indomethacin is probably not warranted.
去氨加压素（dDAVP）是精氨酸加压素的合成类似物，通常经鼻内给药，在治疗尿崩症方面非常有效。然而，在几种临床情况下，胃肠外给药途径可能更可取。我们对6例尿崩症患者进行了研究，结果显示皮下注射0.5至4微克去氨加压素存在剂量反应关系。非甾体抗炎药吲哚美辛可增强对0.5微克去氨加压素的反应强度，但不影响反应持续时间。这些观察结果表明，通常注射1或2微克的去氨加压素在治疗尿崩症方面将是一种有价值的药物，并且可能不需要与吲哚美辛联合治疗。
